JP2010504280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504280A5 JP2010504280A5 JP2009520761A JP2009520761A JP2010504280A5 JP 2010504280 A5 JP2010504280 A5 JP 2010504280A5 JP 2009520761 A JP2009520761 A JP 2009520761A JP 2009520761 A JP2009520761 A JP 2009520761A JP 2010504280 A5 JP2010504280 A5 JP 2010504280A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- chloro
- triazol
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 T-Butyl Chemical group 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004429 atom Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 3
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 3
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- XQQNPZZMXRJVDN-UHFFFAOYSA-N 3,4-dichloro-n-[5-chloro-2-[4-(1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]pyridin-3-yl]benzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=CN1C=1C=CNN=1 XQQNPZZMXRJVDN-UHFFFAOYSA-N 0.000 claims 1
- FZFLWOHYWMSSFG-UHFFFAOYSA-N 4-chloro-n-[5-chloro-2-[4-(4-methyl-1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CNN=C1N1C(C=2C(=CC(Cl)=CN=2)NS(=O)(=O)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=NN=C1 FZFLWOHYWMSSFG-UHFFFAOYSA-N 0.000 claims 1
- JELORYBSSKXTKS-UHFFFAOYSA-N 5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-n,n-dimethyl-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)N(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 JELORYBSSKXTKS-UHFFFAOYSA-N 0.000 claims 1
- HMCRGZKZGJIKHJ-UHFFFAOYSA-N 5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-n-methyl-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)NC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 HMCRGZKZGJIKHJ-UHFFFAOYSA-N 0.000 claims 1
- KPBBXPDMTLDHTE-UHFFFAOYSA-N 5-[3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]-5-methylpyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1S(=O)(=O)NC1=CC(C)=CN=C1C1=NN=C(C(N)=O)N1C=1C=CON=1 KPBBXPDMTLDHTE-UHFFFAOYSA-N 0.000 claims 1
- QHAFGHWVHRRHSV-UHFFFAOYSA-N 5-[3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]-5-methylpyridin-2-yl]-4-phenyl-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1S(=O)(=O)NC1=CC(C)=CN=C1C1=NN=C(C(N)=O)N1C1=CC=CC=C1 QHAFGHWVHRRHSV-UHFFFAOYSA-N 0.000 claims 1
- NUOLRQJDNCPPQU-UHFFFAOYSA-N 5-[5-chloro-3-[(3,4-dichlorophenyl)sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 NUOLRQJDNCPPQU-UHFFFAOYSA-N 0.000 claims 1
- CWEXICJJEOCLLQ-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 CWEXICJJEOCLLQ-UHFFFAOYSA-N 0.000 claims 1
- SAIRUSJXGAIIKQ-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-n-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)NC(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 SAIRUSJXGAIIKQ-UHFFFAOYSA-N 0.000 claims 1
- QDTKHLLJQIJDAD-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(N)=O)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 QDTKHLLJQIJDAD-UHFFFAOYSA-N 0.000 claims 1
- MYDSZQFQVRXQPG-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n,n-dimethyl-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 MYDSZQFQVRXQPG-UHFFFAOYSA-N 0.000 claims 1
- BTFFJIJPEWHEEM-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n,n-dimethyl-4-propan-2-yl-1,2,4-triazole-3-carboxamide Chemical compound CC(C)N1C(C(=O)N(C)C)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 BTFFJIJPEWHEEM-UHFFFAOYSA-N 0.000 claims 1
- DDTYMWFASCHUPO-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n-ethyl-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)NCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 DDTYMWFASCHUPO-UHFFFAOYSA-N 0.000 claims 1
- GUNCDSYWZPBVIR-UHFFFAOYSA-N 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-n-ethyl-n-methyl-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=CON=C1N1C(C(=O)N(C)CC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 GUNCDSYWZPBVIR-UHFFFAOYSA-N 0.000 claims 1
- ZOPRRQNFZVBNDG-UHFFFAOYSA-N 5-[5-chloro-3-[[4-methyl-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxamide Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=C(C(N)=O)N1C1=NOC=C1 ZOPRRQNFZVBNDG-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- PYJQQZKGTZDDHZ-UHFFFAOYSA-N C1(=CC=CC=C1)S(=O)(=O)NC=1C(=NC=C(C=1)C)C1=NN=CN1C1CNCC1 Chemical compound C1(=CC=CC=C1)S(=O)(=O)NC=1C(=NC=C(C=1)C)C1=NN=CN1C1CNCC1 PYJQQZKGTZDDHZ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010063725 Idiopathic pneumonia syndrome Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- BKAKNTTWTRQBBK-UHFFFAOYSA-N O=C(C1=NN=C(C(C=C2)=NC=C2Cl)N1C1=NOC=C1)N1CCOCC1 Chemical compound O=C(C1=NN=C(C(C=C2)=NC=C2Cl)N1C1=NOC=C1)N1CCOCC1 BKAKNTTWTRQBBK-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000001760 anti-analgesic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VXHXALJHPTYTDH-UHFFFAOYSA-N ethyl 5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-4-propan-2-yl-1,2,4-triazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 VXHXALJHPTYTDH-UHFFFAOYSA-N 0.000 claims 1
- LWNVJYPBMIIDOF-UHFFFAOYSA-N ethyl 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-(1,2-oxazol-3-yl)-1,2,4-triazole-3-carboxylate Chemical compound C1=CON=C1N1C(C(=O)OCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LWNVJYPBMIIDOF-UHFFFAOYSA-N 0.000 claims 1
- PWQMLLBKSFCCRB-UHFFFAOYSA-N ethyl 5-[5-chloro-3-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]pyridin-2-yl]-4-propan-2-yl-1,2,4-triazole-3-carboxylate Chemical compound CC(C)N1C(C(=O)OCC)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 PWQMLLBKSFCCRB-UHFFFAOYSA-N 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000007915 ichthyosis prematurity syndrome Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- JTDBSXSLPVDHRS-UHFFFAOYSA-N n-[2-(5-amino-4-propan-2-yl-1,2,4-triazol-3-yl)-5-chloropyridin-3-yl]-4-chloro-3-(trifluoromethyl)benzenesulfonamide Chemical compound CC(C)N1C(N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 JTDBSXSLPVDHRS-UHFFFAOYSA-N 0.000 claims 1
- BLTWVOMRRFJFON-UHFFFAOYSA-N n-[2-(5-amino-4-propan-2-yl-1,2,4-triazol-3-yl)-5-chloropyridin-3-yl]-4-tert-butylbenzenesulfonamide Chemical compound CC(C)N1C(N)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 BLTWVOMRRFJFON-UHFFFAOYSA-N 0.000 claims 1
- ZHABSIKVUSRSKW-UHFFFAOYSA-N n-[2-[4-(4-bromo-1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=CN1C1=NNC=C1Br ZHABSIKVUSRSKW-UHFFFAOYSA-N 0.000 claims 1
- IUCAQAZBATXHQF-UHFFFAOYSA-N n-[2-[5-bromo-4-(1,2-oxazol-3-yl)-1,2,4-triazol-3-yl]-5-chloropyridin-3-yl]-4-chloro-3-(trifluoromethyl)benzenesulfonamide Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(S(=O)(=O)NC=2C(=NC=C(Cl)C=2)C=2N(C(Br)=NN=2)C2=NOC=C2)=C1 IUCAQAZBATXHQF-UHFFFAOYSA-N 0.000 claims 1
- WLIXWPBIQOBJGW-UHFFFAOYSA-N n-[2-[5-bromo-4-(4-bromo-1h-pyrazol-5-yl)-1,2,4-triazol-3-yl]-5-chloropyridin-3-yl]-3,4-dichlorobenzenesulfonamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1S(=O)(=O)NC1=CC(Cl)=CN=C1C1=NN=C(Br)N1C1=NNC=C1Br WLIXWPBIQOBJGW-UHFFFAOYSA-N 0.000 claims 1
- MCUNGNKSMZSFRI-UHFFFAOYSA-N n-[5-[3-[(4-tert-butylphenyl)sulfonylamino]-5-chloropyridin-2-yl]-4-propan-2-yl-1,2,4-triazol-3-yl]acetamide Chemical compound CC(C)N1C(NC(C)=O)=NN=C1C1=NC=C(Cl)C=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 MCUNGNKSMZSFRI-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83104206P | 2006-07-14 | 2006-07-14 | |
| US60/831,042 | 2006-07-14 | ||
| US94585407P | 2007-06-22 | 2007-06-22 | |
| US60/945,854 | 2007-06-22 | ||
| PCT/US2007/015786 WO2008008375A2 (en) | 2006-07-14 | 2007-07-10 | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010504280A JP2010504280A (ja) | 2010-02-12 |
| JP2010504280A5 true JP2010504280A5 (https=) | 2012-02-16 |
| JP5320291B2 JP5320291B2 (ja) | 2013-10-23 |
Family
ID=38670575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520761A Active JP5320291B2 (ja) | 2006-07-14 | 2007-07-10 | トリアゾリルピリジルベンゼンスルホンアミド類 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7683176B2 (https=) |
| EP (1) | EP2049515B1 (https=) |
| JP (1) | JP5320291B2 (https=) |
| CN (1) | CN101511800B (https=) |
| AT (1) | ATE496905T1 (https=) |
| AU (1) | AU2007272972B2 (https=) |
| CA (1) | CA2657670C (https=) |
| DE (1) | DE602007012261D1 (https=) |
| ES (2) | ES2358618T3 (https=) |
| WO (1) | WO2008008375A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1748989A2 (en) * | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7683176B2 (en) | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| EP2276731A1 (en) * | 2008-04-09 | 2011-01-26 | Boehringer Ingelheim International GmbH | 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| CN103209960A (zh) * | 2010-07-26 | 2013-07-17 | 百时美施贵宝公司 | 用作cyp17抑制剂的磺酰胺化合物 |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| ES2656012T3 (es) | 2013-02-06 | 2018-02-22 | Bayer Cropscience Aktiengesellschaft | Derivados de pirazol sustituidos con halógeno como pesticidas |
| SG11201600726QA (en) | 2013-07-29 | 2016-03-30 | Merck Patent Gmbh | 1,3-disubstituted cyclopentane derivatives |
| EP3076968B1 (en) * | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
| AU2014372638A1 (en) | 2013-12-23 | 2016-06-16 | Norgine B.V. | Compounds useful as CCR9 modulators |
| JP2017503772A (ja) | 2013-12-23 | 2017-02-02 | ノージン ビーブイ | Ｃｃｒ９阻害剤としてのベンゼンスルホンアミド |
| HK1232147A1 (zh) * | 2014-03-21 | 2018-01-05 | Tobira Therapeutics, Inc. | 用於治疗纤维化的赛尼克韦罗 |
| MX2017004344A (es) | 2014-10-06 | 2017-06-07 | Chemocentryx Inc | COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDAD INFLAMATORIA DE INTESTINO USANDO UNA TERAPIA DE COMBINACION DE INHIBIDORES DE MOLECULA PEQUENA DEL RECEPTOR DE QUIMIOCINA C-C TIPO 9 (CCR9) Y ANTICUERPOS BLOQUEADORES ANTI-A4ß7 INTEGRINA. |
| CN104341389A (zh) * | 2014-10-19 | 2015-02-11 | 湖南华腾制药有限公司 | 一种三唑哌啶盐酸盐的制备方法 |
| DK3300500T3 (da) | 2015-05-20 | 2020-05-18 | Amgen Inc | Triazolagonister af apj-receptoren |
| US10000458B2 (en) * | 2016-03-31 | 2018-06-19 | Sumitomo Chemical Company, Limited | Production method of 1, 2, 4-triazole compound |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| SG11201810602YA (en) * | 2016-06-03 | 2018-12-28 | Chemocentryx Inc | Method of treating liver fibrosis |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN115504986B (zh) | 2017-03-03 | 2024-05-14 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| WO2019016066A1 (de) | 2017-07-18 | 2019-01-24 | Bayer Cropscience Aktiengesellschaft | Substituierte 3-heteroaryloxy-1h-pyrazole sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| CN114555080B (zh) | 2019-10-16 | 2025-10-10 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯胺 |
| AU2020368393B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| TWI904146B (zh) | 2020-03-31 | 2025-11-11 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
| CN115477626B (zh) * | 2021-06-16 | 2024-08-02 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物及其用途 |
| CN118206536A (zh) * | 2022-12-15 | 2024-06-18 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物的固体形式 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0612247A1 (de) | 1991-11-15 | 1994-08-31 | Byk Gulden Lomberg Chemische Fabrik GmbH | Verwendung von sulfonylverbindungen |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| GB2376691B (en) | 2000-06-01 | 2004-06-23 | Nippon Steel Chemical Co | Organic electroluminescent element material and organic electroluminescent element |
| US7227035B2 (en) * | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) * | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US20060111351A1 (en) * | 2002-11-18 | 2006-05-25 | Solomon Ungashe | Aryl sulfonamides |
| US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| US6939885B2 (en) * | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2005004818A2 (en) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| JP4322062B2 (ja) * | 2003-07-23 | 2009-08-26 | 日本発條株式会社 | エンジンブロックおよびその製造方法 |
| JP5090730B2 (ja) | 2004-03-03 | 2012-12-05 | 株式会社きもと | 光制御フィルムおよびそれを用いたバックライト装置 |
| EP1748989A2 (en) * | 2004-05-12 | 2007-02-07 | ChemoCentryx Inc | Aryl sulfonamides |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| ES2440965T3 (es) * | 2005-01-14 | 2014-01-31 | Chemocentryx, Inc. | Heteroaril-sulfonamidas y CCR2 |
| WO2007014054A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| WO2007014008A2 (en) | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| US7683176B2 (en) * | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| MX2009000395A (es) | 2006-07-14 | 2009-01-29 | Chemocentryx Inc | Triazolil fenil bencenosulfonamidas. |
| US7718683B2 (en) * | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| US20100234364A1 (en) | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
-
2007
- 2007-07-10 US US11/775,601 patent/US7683176B2/en active Active
- 2007-07-10 ES ES07810331T patent/ES2358618T3/es active Active
- 2007-07-10 EP EP07810331A patent/EP2049515B1/en active Active
- 2007-07-10 CA CA2657670A patent/CA2657670C/en active Active
- 2007-07-10 DE DE602007012261T patent/DE602007012261D1/de active Active
- 2007-07-10 WO PCT/US2007/015786 patent/WO2008008375A2/en not_active Ceased
- 2007-07-10 CN CN200780033360XA patent/CN101511800B/zh active Active
- 2007-07-10 AT AT07810331T patent/ATE496905T1/de not_active IP Right Cessation
- 2007-07-10 ES ES07836049T patent/ES2360741T3/es active Active
- 2007-07-10 JP JP2009520761A patent/JP5320291B2/ja active Active
- 2007-07-10 AU AU2007272972A patent/AU2007272972B2/en active Active
-
2010
- 2010-02-19 US US12/708,900 patent/US8445518B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504280A5 (https=) | ||
| CA2657670A1 (en) | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation | |
| CN105764514B (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| JP5423675B2 (ja) | アゾール化合物 | |
| JP2020516671A5 (https=) | ||
| JP2006500348A5 (https=) | ||
| TW200806611A (en) | Novel amidopropionic acid derivatives and medicine containing the same | |
| JP2007510689A5 (https=) | ||
| JP2019504009A5 (https=) | ||
| JP2012525349A5 (https=) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2014511869A5 (https=) | ||
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| AU2011238616A1 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
| RU2009111113A (ru) | Мидуляторы mglur5 | |
| JP2010533158A5 (https=) | ||
| JP2007530690A5 (https=) | ||
| JP2008526723A5 (https=) | ||
| JP2018527336A5 (https=) | ||
| JP2005517006A5 (https=) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2014517833A5 (https=) | ||
| TW201038586A (en) | Sulfonamide derivatives | |
| CN101796038A (zh) | *唑酪氨酸激酶抑制剂 | |
| JP2005536458A5 (https=) |